Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Friedman, James ^a   Alam, S Munir ^a   Shen, Xiaoying ^a   Xia, Shi Mao ^a   Stewart, Shelley ^a   Anasti, Kara ^a   Pollara, Justin ^a   Fouda, Genevieve G ^a   Yang, Guang ^a   Kelsoe, Garnett ^a   Ferrari, Guido ^a   Tomaras, Georgia D ^a   Haynes, Barton F ^a   Liao, Hua Xin ^a   Moody, M Anthony ^a   Permar, Sallie R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH07; MONOCLONAL ANTIBODY CH08; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY;

ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; COLOSTRUM; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LACTATION; MUCOSA CELL; PROTEIN ANALYSIS; PROTEIN DOMAIN; VIRUS NEUTRALIZATION; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PREGNANCY; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; COLOSTRUM; EPITOPES, B-LYMPHOCYTE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; NEUTRALIZATION TESTS; PREGNANCY;

EID: 84862080740     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037648     Document Type: Article

References (49)

1. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD, (2011) B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 17: 108-116.
2. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
3. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954.
4. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
5. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84: 1302-1313.
6. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206.
7. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, et al. (2009) The 'immunologic advantage' of HIV-exposed seronegative individuals. Aids 23: 161-175.
8. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, et al. (2009) HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2: 412-426.
9. Tuaillon E, Valea D, Becquart P, Al Tabaa Y, Meda N, et al. (2009) Human milk-derived B cells: a highly activated switched memory cell population primed to secrete antibodies. J Immunol 182: 7155-7162.
10. Roux ME, McWilliams M, Phillips-Quagliata JM, Weisz-Carrington P, Lamm ME, (1977) Origin of IgA-secreting plasma cells in the mammary gland. J Exp Med 146: 1311-1322.
11. Czinn SJ, Robinson J, Lamm ME, (1987) Chemotaxis as a mechanism for recruitment of mucosal plasma cell precursors. Adv Exp Med Biol 216A: 305-311.
12. McDermott MR, Bienenstock J, (1979) Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 122: 1892-1898.
13. Fouda GG, Yates NL, Pollara J, Shen X, Overman GR, et al. (2011) HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol.
14. Permar SR, Wilks AB, Ehlinger EP, Kang HH, Mahlokozera T, et al. (2010) Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys. J Virol 84: 8209-8218.
15. Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, et al. (2010) Robust vaccine-elicited cellular immune responses in breast milk following systemic Simian Immunodeficiency Virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol 185: 7097-7106.
16. Permar SR, Kang HH, Carville A, Mansfield KG, Gelman RS, et al. (2008) Potent simian immunodeficiency virus-specific cellular immune responses in the breast milk of simian immunodeficiency virus-infected, lactating rhesus monkeys. J Immunol 181: 3643-3650.
17. Morris L, Chen X, Alam M, Tomaras G, Zhang R, et al. (2011) Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 6: e23532.
18. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, et al. (2011) Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. J Virol.
19. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, et al. (2009) High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 158: 171-179.
20. Volpe JM, Cowell LG, Kepler TB, (2006) SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22: 438-444.
21. Stothard P, (2000) The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques 28: 1102, 1104.
22. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154-1163.
23. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, et al. (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85: 11502-11519.
24. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.
25. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224.
26. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, et al. (2011) H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 6: e25797.
27. Ritz C, Spiess AN, (2008) qpcR: an R package for sigmoidal model selection in quantitative real-time polymerase chain reaction analysis. Bioinformatics 24: 1549-1551.
28. Alam SM, Paleos CA, Liao HX, Scearce R, Robinson J, et al. (2004) An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. AIDS Res Hum Retroviruses 20: 836-845.
29. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
30. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 99: 6913-6918.
31. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
32. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, et al. (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79: 603-612.
33. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, et al. (2010) Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 207: 763-776.
34. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
35. Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, et al. (2011) Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol 85: 1340-1347.
36. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289.
37. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
38. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, et al. (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208: 2237-2249.
39. Verkoczy L, Kelsoe G, Moody MA, Haynes BF, (2011) Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 23: 383-390.
40. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A 101: 2706-2711.
41. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
42. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, et al. (2011) An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85: 7029-7036.
43. Nadas A, Zhong P, Burda S, Zekeng L, Urbanski M, et al. (2004) Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies. AIDS Res Hum Retroviruses 20: 55-65.
44. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, et al. (2000) Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 74: 7096-7107.
45. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, et al. (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96: 667-676.
46. Haynes BF, Nicely NI, Alam SM, (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? Nat Struct Mol Biol 17: 543-545.
47. Lopalco L, De Santis C, Meneveri R, Longhi R, Ginelli E, et al. (1993) Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain. Eur J Immunol 23: 2016-2021.
48. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, et al. (1988) Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A 85: 1932-1936.
49. Freed EO, Myers DJ, Risser R, (1990) Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A 87: 4650-4654.